CA80401L3083
© BusinessWire
29.01.2026
MSCL
LISTED
TSX
Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer (“CDO”) and Head of Regulatory Affairs. Ms. Paone brings extensive exper...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
MSCL
LISTED
TSX
Satellos Announces Share Consolidation in Connection with Proposed Nasdaq Listing
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announces that the Company has completed a consolidation of its outstanding common shares (the “Common Shares”) on the basis of one post-consolidat...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2025
MSCL
LISTED
TSX
Satellos Receives Clearance by U.S. FDA and Global Regulators to Initiate Pediatric Phase 2 Study of SAT-3247 for Duchenne Muscular Dystrophy
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it has received Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA), as well as other global reg...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
25.11.2025
MSCL
LISTED
TSX
Satellos to Participate in December Investor Conferences
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will participate in the following investor conferences:
Piper Sandler 37th Annual Healthcare Conference (New York, NY)
Date: Wed...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
18.11.2025
MSCL
LISTED
TSX
Satellos Announces Publication in Nature Communications Supporting its Novel Treatment Approach for Duchenne Muscular Dystrophy
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the publication in Nature Communications of new research from a scientific team at the Ottawa Hospital Research Institute (OHRI) that val...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2025
MSCL
LISTED
TSX
Satellos Reports Third Quarter 2025 Results and Announces Appointment of Mark Nawacki to Board of Directors
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced its financial results for the third quarter ended September 30, 2025, and other corporate and clinical updates.
“The second half of 202...
Themefolio
Profiler
Peergroup
© BusinessWire
30.10.2025
MSCL
LISTED
TSX
Satellos to Participate in November Investor Conferences
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that its leadership team will present and participate in the following investor conferences:
Guggenheim 2nd Annual Healthcare Innovatio...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2025
MSCL
LISTED
TSX
Satellos Announces First Adult Patient Dosed in LT-001, an Open-Label, Long-Term Follow-Up Study of SAT-3247 in Duchenne Muscular Dystrophy
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that the first patient has been dosed in the open-label, long-term follow-up study (LT-001) of SAT-3247 in adult males with Duchenne musc...
Themefolio
Profiler
Peergroup
© BusinessWire
10.10.2025
MSCL
LISTED
TSX
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced new data further demonstrating tolerability and initial efficacy of SAT-3247 in adults (aged 20-27 years) with Duchenne muscular dystroph...
Themefolio
Profiler
Peergroup
© BusinessWire
22.09.2025
MSCL
LISTED
TSX
Satellos Announces IND Submission to the U.S. FDA and Global Regulatory Filings to Advance a Phase 2 Clinical Trial of SAT-3247 in Children with Duchenne Muscular Dystrophy
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA), along with parallel regul...
Themefolio
Profiler
Peergroup
© BusinessWire
21.08.2025
MSCL
LISTED
TSX
Satellos to Participate in Four September Institutional and Retail Investor Conferences
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today that members of its senior management team will participate in the following investor events in September:
Wells Fargo Healthcare Confe...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2025
MSCL
LISTED
TSX
Satellos Reports Second Quarter 2025 Results and Highlights Upcoming Clinical Milestones
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced its financial results and corporate highlights for the second quarter ended June 30, 2025.
“We are excited by the clean safety profile...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
16.07.2025
MSCL
LISTED
TSX
Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer (“CMO”). Dr. Farwell joins Satellos from Dyne Therapeutics (Nasd...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
MSCL
LISTED
TSX
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held June 18, 2025 (the “Meeting”).
Satellos is pleased t...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
MSCL
LISTED
TSX
Satellos Bioscience Shareholders Elect Two New Board Members
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors.
“I am so excited to w...
Themefolio
Profiler
Peergroup
© BusinessWire
16.06.2025
MSCL
LISTED
TSX
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced its participation in the 2025 Parent Project Muscular Dystrophy (PPMD) Annual Conference, taking place June 19–21 in Las...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
MSCL
LISTED
TSX
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced promising Phase 1b data, in an open-label study treating five adult male DMD patients, ages 20 – 27, demonstrating early...
Themefolio
Profiler
Peergroup
© Newsfile
21.05.2025
MSCL
LISTED
TSX
Bloom Burton & Co. Inc. Announces Exercise of Satellos Bioscience Inc. Warrants
News Preview
Toronto, Ontario--(Newsfile Corp. - May 20, 2025) - Bloom Burton & Co. Inc. (Bloom Burton) announces that, today, it exercised 3,200,000 common share purchase warrants (Warrants) of Satellos Bioscience Inc. (Corporation) at $0.50 per share for aggregate consideration of $1,600,000, and the remaining 3,360,474 unexercised Warrants expired. This...
Themefolio
Profiler
Peergroup
© BusinessWire
13.05.2025
MSCL
LISTED
TSX
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced its financial results and corporate highlights for the first quarter ended March 31, 2025.
“We are very pleased with our continued progr...
Themefolio
Profiler
Peergroup
© BusinessWire
07.05.2025
MSCL
LISTED
TSX
Satellos to Present at the CureDuchenne FUTURES National Conference
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the CureDuchenne FUTURES National Conference, taking place in San Antonio, TX, from May 22 to 25.
Satellos Co-founder and CEO Frank Glee...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
MSCL
LISTED
TSX
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present at the 2025 Bloom Burton & Co. Healthcare Investor Conference taking place in Toronto on May 5 and 6.
Satellos Co-founder and CEO Frank...
Themefolio
Profiler
Peergroup
© BusinessWire
02.04.2025
MSCL
LISTED
TSX
Satellos to Participate in Two April Investor Conferences
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, will present and participate at the following investor conferences in April:
Oppenheimer Innovation on the Island
Format: Presentation
Date: Thurs., Apr...
Themefolio
Profiler
Peergroup
© BusinessWire
26.03.2025
MSCL
LISTED
TSX
Satellos Reports 2024 Financial Results and Highlights Company Progress
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today its financial results and corporate highlights for the fourth quarter ended December 31, 2024. All references to currency in this press r...
Themefolio
Profiler
Peergroup
© BusinessWire
19.03.2025
MSCL
LISTED
TSX
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced initial Phase 1 data in an oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific C...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
MSCL
LISTED
TSX
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced an oral presentation at the upcoming 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conferenc...
Themefolio
Profiler
Peergroup
© BusinessWire
10.02.2025
MSCL
LISTED
TSX
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced it has completed enrollment of all four multiple-ascending dose (MAD) cohorts for the Phase 1 clinical trial of SA...
Themefolio
Profiler
Peergroup
© BusinessWire
04.02.2025
MSCL
LISTED
TSX
Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will present at and participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference...
Themefolio
Profiler
Peergroup
© Newsfile
20.12.2024
MSCL
LISTED
TSX
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
News Preview
Toronto, Ontario--(Newsfile Corp. - December 20, 2024) - Bloom Burton & Co. Inc. (Bloom Burton) announces that, today, it acquired 1,692,250 common shares (Shares) of Satellos Bioscience Inc. (Corporation) in connection with a public offering of the Corporation by way of a prospectus supplement dated December 17, 2024 to the short form prospect...
Themefolio
Profiler
Peergroup
© BusinessWire
20.12.2024
MSCL
LISTED
TSX
Satellos Announces Closing of US$40M Public Offering
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced that it has closed an equity offering, issuing a total of 63,285,000 equity securities for gross proceeds of appro...
Themefolio
Profiler
Peergroup
© PR Newswire
17.12.2024
MSCL
LISTED
TSX
Canadian Investment Regulatory Organization Trade Resumption - MSCL
News Preview
TORONTO, Dec. 17, 2024 /CNW/ - Trading resumes in:
Company: Satellos Bioscience Inc.
TSX Symbol: MSCL
All Issues: Yes
Resumption (ET): 9:30 AM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the natio...
Themefolio
Profiler
Peergroup
© BusinessWire
17.12.2024
MSCL
LISTED
TSX
Satellos Announces Pricing of US$40M Overnight Marketed Public Offering
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, is pleased to announce the pricing and terms of its previously announced overnight marketed public offering of common shares of th...
Themefolio
Profiler
Peergroup
© PR Newswire
16.12.2024
MSCL
LISTED
TSX
Canadian Investment Regulatory Organization Trading Halt - MSCL
News Preview
TORONTO, Dec. 16, 2024 /CNW/ - The following issues have been halted by CIRO:
Company: Satellos Bioscience Inc.
TSX Symbol: MSCL
All Issues: Yes
Reason: Pending News
Halt Time (ET): 4:10 PM
CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to en...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
MSCL
LISTED
TSX
Satellos Announces Overnight Marketed Public Offering of Common Shares
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has filed a preliminary prospectus supplement (the “Preliminary Prospectus Supplement”) and intends to fil...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
MSCL
LISTED
TSX
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that the first participant with Duchenne muscular dystrophy (“DMD”) has been dosed in the Phase 1b safety and phar...
Themefolio
Profiler
Peergroup
© BusinessWire
03.12.2024
MSCL
LISTED
TSX
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
News Preview
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) (“Satellos”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Frank Gleeson, Co-founder and CEO will participate in Oppenheimer’s Movers in Rare Disease Summit taking place in New York City...
Themefolio
Profiler
Peergroup
© BusinessWire
02.12.2024
MSCL
LISTED
TSX
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
News Preview
Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced participation in a live investor webinar (the "Webinar") focused on a discussion of Duchenne muscular dystrophy ("DM...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
MSCL
LISTED
TSX
Satellos Appoints Stephanie Brown to Board of Directors
News Preview
Satellos Bioscience Inc. (TSX: MSCL) (OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the appointment of Stephanie Brown to its Board of Directors. Ms. Brown brings over 30 years of biopharma industr...
Themefolio
Profiler
Peergroup
© BusinessWire
13.11.2024
MSCL
LISTED
TSX
Satellos Reports Q3 2024 Financial Results and Provides Clinical Update
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today its financial results and corporate highlights for the three months ended September 30, 2024. All references to currency in this press re...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
MSCL
LISTED
TSX
Satellos to Participate in November 2024 Investor Conferences
News Preview
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that members of the management team of the Company will participate in the following investor conferences.
Gugge...
Themefolio
Profiler
Peergroup
© BusinessWire
01.10.2024
MSCL
LISTED
TSX
Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels
News Preview
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced a presentation of data at the 29th Annual Congress of the World Muscle Society taking place October 8-12, 2024, in...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2024
MSCL
LISTED
TSX
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
News Preview
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that the first participant has been dosed in a Phase 1 clinical study of SAT-3247. SAT-3247 is a novel, oral smal...
Themefolio
Profiler
Peergroup
© BusinessWire
05.09.2024
MSCL
LISTED
TSX
Satellos Announces Participation in September 2024 Investor Conferences
News Preview
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL) (OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that Mr. Frank Gleeson, Co-founder and CEO of Satellos will participate in fireside chats and one-on-one meetings...
Themefolio
Profiler
Peergroup
© BusinessWire
19.08.2024
MSCL
LISTED
TSX
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
News Preview
Satellos Bioscience Inc. (“Satellos” or the “Company”) (TSX: MSCL, OTCQB: MSCLF), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced acceptance of a clinical research proposal to a Human Research Ethics Committee (HREC) in Australia seeking regula...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
MSCL
LISTED
TSX
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
News Preview
Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today its financial results and operational highlights for the three months ended June 30, 2024. All references to curre...
Themefolio
Profiler
Peergroup
© Newsfile
20.09.2023
MSCL
LISTED
TSX
Satellos to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023
News Preview
Toronto, Ontario--(Newsfile Corp. - September 20, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that management will participate in the Cantor Fitzger...
Themefolio
Profiler
Peergroup
© Newsfile
07.09.2023
MSCL
LISTED
TSX
Satellos Bioscience Enters Into an Agreement with ICP Securities Inc. to Provide Market Making Services
News Preview
Toronto, Ontario--(Newsfile Corp. - September 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today that it has entered into an agreement with ICP Secu...
Themefolio
Profiler
Peergroup
© Newsfile
05.09.2023
MSCL
LISTED
TSX
Satellos Expands Leadership Team with New CFO Appointment
News Preview
Elizabeth Williams, CPA, CA, joins as CFO, bringing extensive expertise leading corporate finance and strategy for public biotech companies listed on Nasdaq and TSX.Current CFO, Warren Whitehead, CPA, CMA, transitions to Head of Corporate Strategy to focus on strengthening and expanding collaborations and partnerships.Satellos is advancing a potent...
Themefolio
Profiler
Peergroup
© Newsfile
29.08.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Q2 2023 Financial Results and Operational Highlights
News Preview
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers and Duchenne muscular dystrophy patients Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: M...
Themefolio
Profiler
Peergroup
© Newsfile
02.08.2023
MSCL
LISTED
TSX
Satellos Bioscience Receives Orphan Drug Designation from the U.S. FDA for SAT-3153, a First-in-Class Small Molecule Therapeutic for Duchenne Muscular Dystrophy
News Preview
Company also recently received Rare Pediatric Disease Designation from the FDA for SAT-3153 for the treatment of pediatric patients with DuchenneToronto, Ontario--(Newsfile Corp. - August 2, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutic...
Themefolio
Profiler
Peergroup
© Newsfile
30.06.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Results from Its Annual General Meeting of Shareholders and Adoption of Amendments to Stock Option Plan
News Preview
Toronto, Ontario--(Newsfile Corp. - June 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the results of its annual general meeting of shareholders held virtually on June 29,...
Themefolio
Profiler
Peergroup
© Newsfile
07.06.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Appointment of Chief Medical Officer
News Preview
Dr. Alan K. Jacobs joins Satellos as CMO on June 7th, 2023Toronto, Ontario--(Newsfile Corp. - June 7, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today the appointment of Alan K. J...
Themefolio
Profiler
Peergroup
© Newsfile
01.06.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Grant of Stock Options
News Preview
Toronto, Ontario--(Newsfile Corp. - June 1, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that its board of directors (the "Board") has approved grants of stock options (the "S...
Themefolio
Profiler
Peergroup
© Newsfile
31.05.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces 2023 Q1 Financial Results and Operational Highlights
News Preview
- $55 million equity financing closed- Resourced to advance lead drug candidate into clinical trialsToronto, Ontario--(Newsfile Corp. - May 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseas...
Themefolio
Profiler
Peergroup
© Newsfile
17.05.2023
MSCL
LISTED
TSX
Satellos Bioscience Closes $55M Financing to Support Development of its Lead Drug Candidate for Duchenne Muscular Dystrophy
News Preview
Toronto, Ontario--(Newsfile Corp. - May 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, today announced that it has closed an equity offering, issuing a total of 110 million equity securitie...
Themefolio
Profiler
Peergroup
© Newsfile
11.05.2023
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces Filing of Final Short Form Prospectus for Proposed Offering of Common Shares
News Preview
Toronto, Ontario--(Newsfile Corp. - May 10, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce today that it has filed its final short form prospectus (the "Prospectus") with...
Themefolio
Profiler
Peergroup
© Newsfile
19.04.2023
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces Pricing of Public Offering
News Preview
Toronto, Ontario--(Newsfile Corp. - April 19, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, is pleased to announce the pricing and terms of its previously announced best efforts public offeri...
Themefolio
Profiler
Peergroup
© Newsfile
18.04.2023
MSCL
LISTED
TSX
Satellos Bioscience Inc. Announces Public Offering of Common Shares
News Preview
Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) ("Satellos" or the "Company"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that it has filed a preliminary short form prospectus (the "Preliminary Prospectus")...
Themefolio
Profiler
Peergroup
© Newsfile
31.03.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces 2022 Year End Financial Results and Operational Highlights
News Preview
Toronto, Ontario--(Newsfile Corp. - March 30, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, announced today its financial results and op...
Themefolio
Profiler
Peergroup
© Newsfile
30.03.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Closing of Previously Announced Non-Brokered Offering of $2.385 Million of Unsecured Non-Convertible Debentures
News Preview
Toronto, Ontario--(Newsfile Corp. - March 29, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced it has closed its previously...
Themefolio
Profiler
Peergroup
© Newsfile
23.03.2023
MSCL
LISTED
TSX
Satellos Bioscience Announces Upsize of Proposed Non-Brokered Offering of Unsecured Non-Convertible Debentures to up to $2.385 Million
News Preview
Toronto, Ontario--(Newsfile Corp. - March 22, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, previously announced on March 15, 2023 a pro...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
